Drug Trial Radar · NCT00692770
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Last checked: Nov 20, 2026Latest source record: Aug 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,114
Actual
Start
Aug 15, 2008
Primary completion
Nov 29, 2013
Study completion Nov 28, 2014
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
Conditions
- Carcinoma, Hepatocellular
Interventions
Nexavar (Sorafenib, BAY43-9006)Drug
Sorafenib 400 mg twice daily (BID)
PlaceboDrug
Placebo 2 tablets twice daily (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence Free Survival (RFS) by Independent AssessmentTime frame: From randomization up to 4 years or until disease recurrence whichever came first
Locations
199 sites in 28 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Washington D.C., District of Columbia
Site not named
Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Indianapolis, Indiana
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Burlington, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Minneapolis, Minnesota
Site not named
New York, New York
Site not named
Cleveland, Ohio
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Providence Portland Medical Center
Portland, Oregon
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Houston, Texas
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Seattle, Washington
Site not named
Pilar, Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Camperdown, New South Wales, Australia
Site not named
Randwick, New South Wales, Australia
Site not named
Brisbane, Queensland, Australia
Site not named
Heidelberg, Victoria, Australia
Site not named
Melbourne, Victoria, Australia
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Showing 40 of 199 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.